<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01694264</url>
  </required_header>
  <id_info>
    <org_study_id>H-1112-073-390</org_study_id>
    <nct_id>NCT01694264</nct_id>
  </id_info>
  <brief_title>Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα</brief_title>
  <official_title>A Randomized, Double-blinded, Phase 3, Multicenter, Investigator-initiated Trial for Entecavir for Prophylaxis of Hepatitis B Virus (HBV) Reactivation in HBV Surface Antigen or Anti-HBc Positive Patients Undergoing Anti-TNFα Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyung Hee University Hospital at Gangdong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daegu Catholic University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eulji University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SMG-SNU Boramae Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ewha Womans University Mokdong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inha University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dong-A University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Analysis of effect of anti-TNFα treatment on HBV reactivation among patients with systemic&#xD;
      rheumatic disease, especially rheumatoid arthritis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biologic agents, especially anti-TNFα treatments are widely used in inflammatory arthritis&#xD;
      such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS). More than 60% of RA or AS&#xD;
      patients achieve good clinical response to anti-TNFα treatment. However, TNFα is also an&#xD;
      important mediator participating in the normal immune response to infectious agents, in&#xD;
      particular intracellular microorganisms in the human body. Therefore, opportunistic&#xD;
      infections such as tuberculosis, viral and fungal infections have been of concern when using&#xD;
      anti-TNFα agents. With accumulating experience, the treatment guideline for anti-TNFα therapy&#xD;
      in latent tuberculosis is now well established. It is noteworthy that there are a number of&#xD;
      case reports describing hepatitis B virus (HBV) reactivation in otherwise asymptomatic&#xD;
      carriers who received anti-TNFα treatment. Anti-TNFα agents are now utilized as a promising&#xD;
      treatment regimen for RA and AS treatment for even HBsAg carriers, yet there are still&#xD;
      concerns of the risk of anti-TNFα therapy contributing to HBV reactivation. In our previous&#xD;
      studies, we found that anti-viral therapy before starting anti-TNFα treatment may reduce the&#xD;
      incidence of HBV reactivation, and that entecavir is likely more suitable in long-term&#xD;
      prophylaxis for HBsAg carriers under anti-TNFα treatment. This justifies the need of a&#xD;
      prospective trial that could demonstrate the long-term effects of prophylaxis in using&#xD;
      anti-TNFα therapy in this subgroup of patients. It would help clinicians understand 1)&#xD;
      whether anti-viral therapy is necessary in inactive HBsAg carriers initiating anti-TNFα&#xD;
      treatment, and 2) at what time point would we most likely witness HBV reactivation after&#xD;
      starting anti-TNFα therapy without anti-viral therapy coverage. In addition to established&#xD;
      nationwide network of Rheumatologists working in major academic institutes in Korea, our&#xD;
      division in Seoul National University Hospital has led many multi-center trials throughout&#xD;
      the past years. In summary, the question of whether to combine anti-viral prophylaxis in&#xD;
      HBsAg carriers starting anti-TNFα therapy is an important issue to Rheumatologists. There is&#xD;
      no guideline for managing this subset of patients, and clinicians normally begin anti-viral&#xD;
      therapy after the patient's liver function worsens. Therefore, our nationwide network of&#xD;
      specialists proposes to launch a prospective study to investigate the benefit of anti-viral&#xD;
      prophylaxis with entecavir in HBsAg carriers starting anti-TNFα treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Delayed recruitment, unable to meet calculated sample size&#xD;
  </why_stopped>
  <start_date type="Actual">September 1, 2012</start_date>
  <completion_date type="Actual">December 31, 2015</completion_date>
  <primary_completion_date type="Actual">August 31, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The frequency (events) of HBV reactivation</measure>
    <time_frame>48 weeks</time_frame>
    <description>Elevated HBV DNA titer: ≥1 log10 rise in HBV DNA level compared with baseline level (virologic breakthrough), along with&#xD;
Increase of AST or ALT above 32 x upper limit of normal (ULN) (biochemical breakthrough)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of HBV reactivation among different anti-TNFα treatment groups</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Psoriatic Arthritis</condition>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <other_name>Baraclude (Bristol-Myers Squibb) 0.5mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>placebo, prepared by Bristol-Myers Squibb</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic hepatitis B, inactive HBsAg carriers or anti-HBc antibody positive patients&#xD;
             with AST, ALT level equal or lower than 2x ULN&#xD;
&#xD;
          -  Patient who has systemic rheumatic disease for which anti-TNFα treatment indication&#xD;
             has been approved by the KFDA; rheumatoid arthritis (RA, 1987 ACR criteria),&#xD;
             ankylosing spondylitis (AS, modified New York criteria), psoriatic arthritis (PsA,&#xD;
             modified ESSG criteria), and juvenile rheumatoid arthritis (JRA, 1977 ACR criteria).&#xD;
&#xD;
          -  Patient who is eligible to start anti-TNFα treatment (etanercept, infliximab,&#xD;
             adalimumab, golimumab, and certolizumab pegol) due to treatment failure of other&#xD;
             DMARDs against underlying RA, AS, PsA, or JRA. Patient who also fully understands that&#xD;
             anti-TNFα agent expenses are not covered in this study.&#xD;
&#xD;
          -  Patient who is willing and able to comply with the study drug regimen and all other&#xD;
             study requirements&#xD;
&#xD;
          -  Patient who is willing and able to provide a written informed consent to participate&#xD;
             in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who has liver cirrhosis or a history of hepatocellular carcinoma (HCC) or&#xD;
             findings suggestive of HCC, such as suspicious foci or elevated serum alpha&#xD;
             fetoprotein (AFP)&#xD;
&#xD;
          -  Patient who received interferon or other immunomodulatory treatment for HBV infection&#xD;
             in the 12 months before screening for this study&#xD;
&#xD;
          -  Patient who has concomitant other chronic viral infection (HCV or HIV)&#xD;
&#xD;
          -  Patient who is pregnant or breastfeeding or willing to be pregnant&#xD;
&#xD;
          -  A history of chronic infection, recent serious or life-threatening infection.&#xD;
             Especially,&#xD;
&#xD;
               -  Patient with current clinical or laboratory evidence of active tuberculosis (TB)&#xD;
                  or latent TB unless there is documentation of prior anti-TB treatment was&#xD;
                  appropriate in duration according to the Korea Food and Drug Administration&#xD;
                  (KFDA) guidelines for management of latent TB in patients being treated with&#xD;
                  biologic agents&#xD;
&#xD;
               -  Patient with a history of herpes zoster within 2 months before screening for this&#xD;
                  study&#xD;
&#xD;
          -  Active malignancy or a history of treated malignancy less than 5 years prior to&#xD;
             screening&#xD;
&#xD;
          -  Patients who are not cooperative or unable to comply with the study procedures&#xD;
&#xD;
          -  Patients with any other condition which the investigator's judgment would make the&#xD;
             patient unsuitable for inclusion in the study such as alcohol and drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yeong wook Song, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Rheumatology, Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University, College of Medicine</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejun</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daejun Eulji University Hospital</name>
      <address>
        <city>Daejun</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Gangdong Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyunghee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Yeouido St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>September 24, 2012</study_first_submitted>
  <study_first_submitted_qc>September 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2012</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Yeong-Wook Song</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HBV surface antigen</keyword>
  <keyword>Anti-HBc positive</keyword>
  <keyword>Anti-TNFα Treatment</keyword>
  <keyword>Reactivation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01694264
org study id: H-1112-073-390
nct id: NCT01694264
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
has dmc: No
Analysis of effect of anti-TNFα treatment on HBV reactivation among patients with systemic
      rheumatic disease, especially rheumatoid arthritis
Biologic agents, especially anti-TNFα treatments are widely used in inflammatory arthritis
      such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS). More than 60% of RA or AS
      patients achieve good clinical response to anti-TNFα treatment. However, TNFα is also an
      important mediator participating in the normal immune response to infectious agents, in
      particular intracellular microorganisms in the human body. Therefore, opportunistic
      infections such as tuberculosis, viral and fungal infections have been of concern when using
      anti-TNFα agents. With accumulating experience, the treatment guideline for anti-TNFα therapy
      in latent tuberculosis is now well established. It is noteworthy that there are a number of
      case reports describing hepatitis B virus (HBV) reactivation in otherwise asymptomatic
      carriers who received anti-TNFα treatment. Anti-TNFα agents are now utilized as a promising
      treatment regimen for RA and AS treatment for even HBsAg carriers, yet there are still
      concerns of the risk of anti-TNFα therapy contributing to HBV reactivation. In our previous
      studies, we found that anti-viral therapy before starting anti-TNFα treatment may reduce the
      incidence of HBV reactivation, and that entecavir is likely more suitable in long-term
      prophylaxis for HBsAg carriers under anti-TNFα treatment. This justifies the need of a
      prospective trial that could demonstrate the long-term effects of prophylaxis in using
      anti-TNFα therapy in this subgroup of patients. It would help clinicians understand 1)
      whether anti-viral therapy is necessary in inactive HBsAg carriers initiating anti-TNFα
      treatment, and 2) at what time point would we most likely witness HBV reactivation after
      starting anti-TNFα therapy without anti-viral therapy coverage. In addition to established
      nationwide network of Rheumatologists working in major academic institutes in Korea, our
      division in Seoul National University Hospital has led many multi-center trials throughout
      the past years. In summary, the question of whether to combine anti-viral prophylaxis in
      HBsAg carriers starting anti-TNFα therapy is an important issue to Rheumatologists. There is
      no guideline for managing this subset of patients, and clinicians normally begin anti-viral
      therapy after the patient's liver function worsens. Therefore, our nationwide network of
      specialists proposes to launch a prospective study to investigate the benefit of anti-viral
      prophylaxis with entecavir in HBsAg carriers starting anti-TNFα treatment.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Prevention
masking: Double (Participant, Investigator)
measure: The frequency (events) of HBV reactivation
time frame: 48 weeks
description: Elevated HBV DNA titer: ≥1 log10 rise in HBV DNA level compared with baseline level (virologic breakthrough), along with
Increase of AST or ALT above 32 x upper limit of normal (ULN) (biochemical breakthrough)
measure: Incidence of HBV reactivation among different anti-TNFα treatment groups
time frame: 72 weeks
arm group label: Experimental Group
arm group type: Experimental
description: Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
arm group label: Control Group
arm group type: Placebo Comparator
description: Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
intervention type: Drug
intervention name: Entecavir
description: Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
arm group label: Experimental Group
other name: Baraclude (Bristol-Myers Squibb) 0.5mg
intervention type: Drug
intervention name: Placebo
description: Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
arm group label: Control Group
other name: placebo, prepared by Bristol-Myers Squibb
criteria: 
gender: All
minimum age: 16 Years
maximum age: 85 Years
healthy volunteers: No
last name: Yeong wook Song, MD, PhD
role: Principal Investigator
affiliation: Division of Rheumatology, Seoul National University Hospital
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Korea, Republic of
responsible party type: Principal Investigator
investigator affiliation: Seoul National University Hospital
investigator full name: Yeong-Wook Song
investigator title: Professor
mesh term: Hepatitis B
mesh term: Hepatitis B, Chronic
mesh term: Spondylitis
mesh term: Arthritis
mesh term: Arthritis, Psoriatic
mesh term: Spondylitis, Ankylosing
mesh term: Arthritis, Juvenile
mesh term: Hepatitis
mesh term: Entecavir